NASDAQ$ARCT
Arcturus Therapeutics Holdings Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Arcturus Therapeutics reported Q4 2025, net loss of $29.1M, diluted EPS of $-1.03.
For Q4 2025, Arcturus Therapeutics reported a net loss of $29.1M, diluted EPS was $-1.03. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Net loss $29.1M.
- Diluted EPS $-1.03.
- Arcturus Therapeutics MD&A covers liquidity, capital, and operating priorities.
Headline financials
Revenue & EPS history
Arcturus Therapeutics · Revenue · Quarterly
$7.2M
Forward guidance
Clinical-stage outlook focuses on trial readouts, cash runway, and regulatory milestones rather than near-term product revenue.
Tailwinds
- Pipeline catalysts and trial enrollment progress.
- Cash runway supports operating plan.
- Partnerships may provide non-dilutive funding.
Headwinds
- Clinical and regulatory risk.
- R&D spend and financing needs.
- Competitive therapies in development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
-3.8%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-3.0%
Avg return
30 days after
38%
18 / 48 earnings
Positive
+27.3%
Q4 2022
Best reaction
-53.9%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.7% | -9.7% | -20.0% | |
| Q4 2025 | -5.2% | -7.0% | +1.5% | |
| Q3 2025 | -1.1% | -17.2% | -14.4% | |
| Q1 2025 | +2.3% | +0.5% | +9.1% | |
| Q4 2024 | -8.9% | -10.7% | -43.0% | |
| Q3 2024 | +7.1% | +6.8% | +4.1% | |
| Q2 2024 | -3.5% | -12.0% | -7.3% | |
| Q1 2024 | -2.8% | +4.2% | +15.5% | |
| Q4 2023 | -2.4% | +2.4% | -15.4% | |
| Q3 2023 | +27.2% | +41.1% | +58.3% | |
| Q2 2023 | -20.0% | -13.6% | -0.2% | |
| Q1 2023 | +3.1% | +7.2% | -0.5% | |
| Q4 2022 | +27.3% | +51.2% | +63.6% | |
| Q3 2022 | -14.9% | -20.1% | -25.9% | |
| Q2 2022 | -16.8% | -8.8% | -28.1% | |
| Q1 2022 | -11.4% | -9.3% | +4.0% | |
| Q4 2021 | -6.6% | -20.3% | +16.5% | |
| Q3 2021 | -3.1% | +0.5% | +5.2% | |
| Q2 2021 | +2.6% | -2.6% | +12.8% | |
| Q1 2021 | -14.4% | -9.2% | +7.2% | |
| Q4 2020 | +2.4% | -18.0% | -21.6% | |
| Q3 2020 | -37.8% | -25.1% | +40.5% | |
| Q2 2020 | -14.4% | -16.2% | -31.3% | |
| Q1 2020 | -5.2% | +11.9% | -21.1% | |
| Q4 2019 | -26.9% | -9.8% | +12.2% | |
| Q3 2019 | -3.1% | -0.3% | +6.9% | |
| Q2 2019 | +16.0% | +16.2% | +16.6% | |
| Q3 2018 | -4.2% | -10.6% | -38.8% | |
| Q1 2018 | -2.9% | -6.7% | +1.6% | |
| Q4 2017 | -6.6% | -5.3% | -39.3% | |
| Q3 2017 | -3.3% | -4.6% | -5.3% | |
| Q2 2017 | +2.0% | +0.0% | +4.9% | |
| Q1 2017 | +3.6% | +4.5% | +2.7% | |
| Q4 2016 | +5.2% | +13.8% | -50.5% | |
| Q3 2016 | +0.8% | -4.2% | -30.8% | |
| Q2 2016 | +3.4% | +5.5% | +2.1% | |
| Q1 2016 | -10.0% | — | — | |
| Q4 2015 | -6.2% | — | — | |
| Q3 2015 | -16.8% | — | — | |
| Q2 2015 | +13.8% | — | — | |
| Q1 2015 | -0.5% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2014 | -53.9% | — | — | |
| Q2 2014 | +5.4% | — | — | |
| Q1 2014 | -0.2% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q3 2013 | -3.2% | — | — | |
| Q2 2013 | +1.2% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro